Quarterly ResultMay 6, 2026, 04:25 PM
Innoviva Q1 Revenue $98.0M, Net Income $186.6M; Product Sales +37%
AI Summary
Innoviva reported a strong start to 2026, with total revenue increasing 11% to $98.0 million and net income reaching $186.6 million for the first quarter. This performance was driven by resilient royalty revenue and significant growth in net product sales, particularly from its Innoviva Specialty Therapeutics (IST) platform. The company also highlighted the FDA approval of NUZOLVENCE and active capital allocation, including share repurchases, underscoring confidence in its long-term value proposition.
Key Highlights
- Total revenue grew 11% to $98.0 million for Q1 2026, up from $88.6 million in Q1 2025.
- Net income was $186.6 million ($2.52 basic EPS) in Q1 2026, compared to a net loss of $46.6 million in Q1 2025.
- Gross royalty revenue from GSK was $58.6 million, down from $61.3 million in Q1 2025.
- Net product sales increased 37% to $41.4 million, with U.S. sales up 29% to $34.2 million.
- Innoviva's strategic healthcare investments were valued at $773.3 million as of March 31, 2026.
- Cash and cash equivalents totaled $603.1 million as of March 31, 2026.
- Repurchased 971,066 shares for $20.4 million under its $125 million share repurchase program.
- NUZOLVENCE received U.S. FDA approval in December 2025 and is on track for H2 2026 availability.